AbbVie gets FDA approval for antibiotic treatment Emblaveo
Subscribe to TheStreet's free daily newsletter 💰💵 That is why the market saw AbbVie make a number of acquisitions to expand ...
It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.
AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...
AbbVie Inc. (NYSE:ABBV) discovers, develops, manufactures and sells pharmaceuticals worldwide. It is set to report the Q4 ...
The Motley Fool on MSN8d
Why AbbVie Stock Is Jumping TodayShares of AbbVie (NYSE: ABBV) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier ...
Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...
The annualized dividend paid by AbbVie is $6.56/share, currently paid in quarterly installments, and its most recent dividend ...
The North Chicago-based drugmaker is relying on newer treatments to make up for falling sales of Humira, its aging ...
The stock's fall snapped a two-day winning streak.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback